Death, Taxes, And Choosing A J&J Therapy For Myeloma

Research evidence excerpt

Death, Taxes, And Choosing A J&J Therapy For Myeloma

own KOL checks as well). Nonetheless, the lack of this J-code has not

prevented growth at a pace faster than what JNJ saw with Darzalex FASPRO or competitor PD-1 inhibitors,

which we perceive as particularly promising. Lastly, the safety profile, which bears have harped on, has been

largely assuaged following the COCOON study, as well as the introduction of a subcutaneous option. Now, its

safety profile rivals that of osimertinib monotherapy, which is the dominant 1L EGFRm lung cancer regimen that

Rybrevant+Lazcluze also demonstrated a survival benefit over in MARIPOSA.

●A word on colorectal cancer. While Rybrevant's expansion into colorectal cancer was not a focus during this call, it

was mentioned as another key opportunity for the brand. Here, the phase 3 OrigAMI-2 and -3 studies are ongoing

to support a registrational package.

More juice to squeeze from Erleada ahead of patent expiry in 2030. The phase 3 PROTEUS data were impressive

and, in our view, practice changing too given no other therapies exist on top of radical prostatectomy at this time (our

take on the plenary session here). We'd underline the 5-year treatment free interval demonstrated by Erleada+ADT,

which improves upon curative-intent surgery and may even allow many patients to never need another therapy again

in their lifetime. The addressable market is not only massive (e.g., 70-80K patients per year per our math), but it is also

expanding as the field adopts new ways of staging and defining what a high-risk patient is. While the key question here

is how much does this change JNJ's previous expectation of Erleada being a $1-5B drug (EBR 2023), the company did not

comment on any adjustments to its long term guidance.